Kailera Therapeutics is trading at $12.85, up +5.76%, alongside biotech-sector gains. - XBI is up 2.13% during the regular session, supporting a sector-related explanation for the move. - No clear company-specific catalyst was identified. Kailera Therapeutics announced November investor-conference appearances, but its release did not link them to the share-price move. - Biotech had recently outperformed broader-market ETFs, providing additional sector context.